| REVIEWS |
|
|
|
|
| Current Development on RNA-based Anti-HIV-1 Gene Therapy |
| CHEN Feng, YANG Yi-shu, ZENG Yi |
| College of Life Science and Bio-engineering, Beijing University of Technology, Beijing 100124, China |
|
|
|
Abstract Acquired immune deficiency syndrome (AIDS) is a high-risk disease which spreads rapidly all over the world since it has been discovered. Although the highly active antiretroviral therapy (HAART) that are widely used in present can improve the quality of life of HIV-1 infected patient dramatically, treatment interruptions have often occurred because of the high cost, drug resistance and side effects. As a result, the new antiretroviral drugs and approaches are demanded for sustained antiretrovial effects. With the development of molecular biology, stem cell, nanotechnology and other related technology, gene therapy for HIV-1 infection has attracted considerable attention in recent years. RNA-based gene therapy for treatment of HIV-1 infection, including antisense RNA, ribozymes, RNA decoys and the RNA interference are focused on. These studies demonstrated that the RNA-based anti-HIV-1 gene therapy may serve as an effective adjuvant to traditional treatments.
|
|
Received: 10 January 2012
Published: 25 June 2012
|
|
|
|
|
[1] Gebo K A, Fleishman J A, Conviser R, et al. Contemporary costs of HIV healthcare in the HAART era. AIDS, 2010, 24: 2705-2715.
[2] Richman D D, Margolis D M, Delaney M, et al. The challenge of finding a cure for HIV infection. Science, 2009, 323: 1304-1307.
[3] Rubanyi G M. The future of human gene therapy. Molecular Aspects of Medicine. 2001, 22: 113-142.
[4] Weiss B, Davidkova G, Zhou L W. Antisense RNA gene therapy for studying and modulating biological processes. Cell Mol Life Sci, 1999, 55: 334-358.
[5] Chan J, Lim S. Antisense oligonucleotides: from to therapeutic application. Clin Exp Pharmacol Physiol, 2006, 33 (5/6): 533-540.
[6] Inouye M. Antisense RNA: its functions and applications in gene regulation-a review. Gene, 1988, 72: 25-34.
[7] Ludwig L B, Ambrus J L, Krawczyk K A, et al. Human immunodeficiency virus-type I LTR DNA contains an intrinsic gene producing antisense RNA and protein products. Retrovirology, 2006, 3: 80-83.
[8] Qureshi A, Zheng R, Parlett T, et al. Gene silencing of HIV chemokine receptors using ribozymes and single-stranded antisense RNA. Biochem J, 2006, 394(Pt 2): 511-518.
[9] Probst J C. Antisense oligodeoxynucleotide and ribozyme design. Methods, 2000, 22(3): 271-281.
[10] Peracchi A. Prospects for antiviral ribozymes and deoxyribozymes. Rev Med Virol, 2004, 14: 47-64.
[11] Mulhbacher J, St-PierreP, Lafontaine D A. Therapeutic applications of ribozymes and riboswitches. Curr Opin Pharmacol, 2010, 10: 551-556.
[12] Scarborough J, Lévesque D, Didierlaurent L, et al. In Vitro and in vivo cleavage of HIV-1 RNA by new SOFA-HDV ribozymes and their potential to inhibit viral replication. RNA Biology, 2011, 8(2):343-353.
[13] Mitsuyasu R T, Merigan T C, Carr A, et al. Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells. Nat Med, 2009, 15: 285-292.
[14] Unwalla H J, Li H T, Li S Y, et al. Use of a U16 snoRNA-containing ribozyme library to identify ribozyme targets in HIV-1. Mol Ther, 2008, 16(6): 1113-1119.
[15] Nazari R, Ma X Z, Joshi S. Inhibition of human immunodeficiency virus-1 entry using vectors expressing a multimeric hammerhead ribozyme targeting the CCR5 mRNA. J Gen Virol, 2008, 89: 2252-2261.
[16] 徐亮, 何军林, 刘克良. 核酶的研究进展. 中国新药杂志. 2006, 15(10): 759-764. Xu L, He J L, Liu K L. Progresses on ribozymes and deoxyribozymes. Chinese Journal of New Drugs, 2006, 15(10): 759-764.
[17] 张丽娜, 姜凤超. 核酶与AIDS治疗. 中国生物化学与分子生物学报. 2007, 23(2): 106-115. Zhang L N, Jiang F C. Ribozymes in AIDS therapy. Chinese Journal of Biochemistry and Molecular Biology, 2007, 23(2): 106-115.
[18] Strayer D S, Akkina R, Bunnell B A. Current status of gene therapy strategies to treat HIV/AIDS. Mol Ther, 2005, 11(6): 823-842.
[19] Cullen B. Mechanism of action of regulatoty proteins encoded by complex retroviruses. Microbiol Rev, 1992, 56: 375-394.
[20] Sullenger B, Gallardo H, Ungers G, et al. Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication. Cell, 1990, 63: 601-608.
[21] Tiley L, Malim M, Tewary H, et al. Identification of a high affinity RNA binding site for the HIV-1 Rev protein. Proc Natl Acad Sci USA, 1992, 89: 758-762.
[22] Lee S, Gallardo H, Gilboa E, et al. Inhibition of HIV-1 in human T-cells by a potent RRE decoy comprised of the 13nt nucleotide long minimal Rev binding domain. J Virol, 1994, 68: 8254-8264.
[23] Li M J, Li H T, Rossi J J. RNAi in Combination with a ribozyme and TAR decoy for treatment of HIV infection in hematopoietic cell gene therapty. Ann N Y Acad Sci, 2006, 1082(1): 172-179.
[24] Carthew R W, Sontheimer E J. Origins and mechanisms of miRNAs and siRNAs. Cell, 2009, 136: 642-655.
[25] Fire A, Xu S Q, Montgomery M K, et al. Potent and specific genetic interference by double-strand RNA in Caenorhabditis elegans. Nature, 1998, 391: 806-811.
[26] Tuschl T, Zamore P D, Lehmann R, et al. Targeted mRNA degradation by double-stranded RNA in vitro. Gene Dev, 1999, 13: 3191-3197.
[27] Ghildiyal M, Zamore P D. Small silencing RNAs: an expanding universe. Nat Rev Genet, 2009, 10: 94-108.
[28] Ryther R C C, Flynt A S, Phillips III J A, et al. SiRNA therapeutics: big potential from small RNAs. Gene Ther, 2005, 12: 5-11.
[29] Liu Y P, Haasnoot J, Brake O, et al. Inhibition of HIV-1 by multiple siRNAs expressed from a single microRNA polycistron. Nucleic Acids Res, 2008, 36(9): 2811-2824.
[30] Ehsani A, Saetrom P, Zhang J, et al. Rational design of micro-RNA-like bifunctional siRNAs targeting HIV and the HIV coreceptor CCR5. Mol Ther, 2010, 18(4): 796-802.
[31] Bertrand J R, Pottier M, Vekris A. Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. Biochem Biophys Res Commun, 2002, 296: 1000-1004.
[32] Jackson A I, Linsley P S. Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat Rev Drug Discov, 2010, 9: 57-67.
[33] Reischl D, Zimmer A. Drug delivery of siRNA therapeutics: potentials and limits of nanosystems. Nanomedicine, 2009, 5: 8-20.
[34] Eguchi A, Meade B R, Chang Y C, et al. Efficient siRNA delivery into primary cells by a peptide. Nat Biotechnol, 2009,27(6):567-571.
[35] Christie R J,Nishiyama N,Kataoka K. Delivering the code: polyplex carriers for deoxyribonucleic acid and ribonucleic acid interference therapies.Eninology,2010,151: 466-473.
[36] Neves J D, Amiji M M, Bahia M F, et al. Nanotechnology-based systems for the treatment and onprevention of HIV/AIDS. Adv Drug Deliver Rev, 2010, 62: 458-477.
[37] Shu Y, Cinier M, Shu D, et al. Assembly of multifunctional phi29 pRNA nanoparticles for specific delivery of siRNA and other therapeutics to targeted cells. Methods, 2011, 54: 204-214.
[38] Zhou J H, Shu Y, Guo P X, et al. Dual functional RNA nanoparticles containing phi29 motor pRNA and anti-gp120 aptamer for cell-type specific delivery and HIV-1 inhibition. Methods, 2011, 54: 284-294. |
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
